Company Overview
The psychiatric treatment market accounts for 7.4% of healthcare spending, second only to heart disease. In the U.S., depression affects more than 18 million people; physicians write 11 million prescriptions per month to treat depression. Other frequently reported central nervous system (CNS) disorders include anxiety, addiction, eating disorders and schizophrenia.
In most medical specialties, physicians base their diagnoses and treatment plans on the results of objective tests. But psychiatric disorders are diagnosed based on the patient’s behavior, or symptoms. Often, a patient is misdiagnosed or given a drug to which the patient is treatment resistant, or one which makes a situation worse. CNS medications are powerful with potentially dangerous side effects. This is problematic when prescriptions for these medications are determined by trial and error.
CNS Response has developed the first proven quantitative approach to guiding the treatment of patients with behavioral disorders. Using data from a digital electroencephalogram (EEG), which is a simple noninvasive procedure to measure brain function or physiology, CNS Response analyzes and then compares the output to a database of over 13,000 medication trials. This Referenced-EEG (rEEG®) is used to match medications to a patient’s individual physiology.
Information from the rEEG® is compiled into a two page report detailing the relative level of abnormality, drug class sensitivity and individual medication responsivity. These summaries provide to a treating physician neuropsychiatric sensitivity and resistance data based on treatment response of individuals that have biomarkers similar to that of their patient. Eight trials involving 500 treatment resistant patients have been conducted, all validating the efficacy of the rEEG profile in guiding treatment. The method has been over 75% effective in treating patients with various CNS disorders that failed to respond to traditional treatments.